Статья
ЛЕЧЕНИЕ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ ПОД КОНТРОЛЕМ КОНЦЕНТРАЦИИ НАТРИЙУРЕТИЧЕСКИХ ПЕПТИДОВ
Натрийуретические пептиды (НУП) являются важными биомаркерами в диагностике и определении прогноза у пациентов с сердечной недостаточностью (СН). Оценка динамики концентрации НУП (BNP, NT-proBNP) может быть использована в качестве критерия успешности проводимой терапии. Так, при достижении целевых уровней НУП можно прогнозировать благоприятный исход заболевания. В настоящее время лечение СН с учетом уровней НУП является частью рекомендаций по лечению СН (класс IIа) и улучшению ее исхода (класс IIб) в США, однако такой подход не используется в российских клиниках.Цель. Представить современный взгляд на возможность использования НУП для оценки эффективности проводимой терапии пациентов с СН.
1. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New ZealandGuidelines for the prevention, detection and management of chronic heart failure in Australia, 2006 / H. Krum// Med. J. Aust. 2011. Vol. 194. P. 405–409.
2. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines / C. W. Yancy// J. Am. Coll. Cardiol. 2013. Vol. 62. e147–239.
3. Bold de A. J. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats // Life Sci. 1981. Vol. 8 P. 89–94.
4. Passino C. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure // J. Am. Coll. Cardiol. 2006. Vol. 47. P. 1835–1839.
5. Al-Meslmani B. M., Fahoum S. K., Shamia M. G. NTproBNP in monitoring treatment of patients with congestive heart failure // Clin. Lab. 2007. Vol. 53. P. 35–39.
6. BNP-guided vs symptom-guided heart failure herapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial / M. Pfisterer// JAMA. 2009. Vol. 301. P. 383–392.
7. Veldhuisen van D. J. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction // J. Am. Coll. Cardiol. 2013.Vol. 61. P. 1498–1506.
8. B-type natriuretic peptide guided treatment of heart failure and all cause mortality: an individual patient data metaanalysis / R. W. Troughton// Eur. Heart J. 2011. Vol. 32 (Suppl. 1). P. 31.
9. O’Neill J. O. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severeheart failure // Am. Heart J. 2005. Vol. 149. P. 363–369.
10. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis / P. Porapakkham// Arch. Intern. Med. 2010. Vol. 170. P. 507–514.
11. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function / G. Cioffi// J. Card. Fail. 2006. Vol. 12. P. 608–615.
12. Characterization and prediction of natriuretic peptide ‘nonresponse’ during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study / H. K. Gaggin// Jr. Congest Heart Fail. 2013. Vol. 19. P. 135–142.
13. Charles C. J. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep // Am. J. Physiol. 1996 Vol. 271. P. 373–380.
14. Concentrations and molecular forms of С-type natriuretic peptide in brain and cerebrospinal fluid / K. Togashi// Clin. Chem. 1992. Vol. 38. P. 2136–2139.
15. Cost analysis and cost-effectiveness of NT-proBNPguided heart failure specialist care in addition to home-based nurse care / C. Adlbrecht// Eur. J. Clin. Invest. 2011. Vol. 41. P. 315–322.
16. Cost-effectiveness of N-terminal Pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure) / Wijk S. Sanders van// JACC Heart Fail. 2013. № 1. P. 64–71.
17. Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure / D. Moertl// Int. J. Technol. Assess. Health. Care. 2013. Vol. 29. P. 3–11.
18. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins / P. J. M. Best// Cardiovasc. Res. 2002. Vol. 55. P. 375–384.
19. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study / A. Bhardwaj// Jr. Am Heart J. 2010. Vol. 159. P. 532–538.
20. Dietz J. R. Release of natriuretic factor from rat heartlung preparation by atrial distention // Am. J. Physiol. 1984. Vol. 247. P. 1093–1096.
21. Masson S. Direct comparison of B-typ natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data // Clin. Chem. 2006. Vol. 52. P. 1528–1538.
22. Gheorghiade М. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial // JAMA. 2013. Vol. 309. P. 1125–1135.
23. Shanmugam N. Effect of atrioventricular optimization on circulating N-terminal pro brain natriuretic peptide following cardiac resynchronization therapy // Eur. J. Heart. Fail. 2013. Vol. 15. P. 534–542.
24. Bayes-Genis А. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea // Arch. Intern. Med. 2007. Vol. 167. P. 400–407.
25. McMurray J. J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure // Circ. Heart Fail. 2008. Vol. 1. P. 17–24.
26. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC / J. J. McMurray// Eur. Heart J. 2012. Vol. 33. P. 1787–1847.
27. Flynn T. G., de Bold M. L., de Bold A. J. The amino acid sequence of an atrial natriuretic peptide with potent diuretic and natriuretic properties // Biochem. Biophys. Res. Commun. 1983. Vol. 117. P. 859–865.
28. Frequency and predictors of hyperkalemia in patients / ј60 years of age with heart failure undergoing intense medical therapy // S. Muzzarelli// Am. J. Cardiol. 2012. Vol. 109. P. 693–698.
29. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) / L. Gullestad// Eur. Heart J. 2012. Vol. 33. P. 2290–2296.
30. Heart failure outcomes and benefits of NT-proBNPguided management in the elderly: results from the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study // H. K. Gaggin// J. Card. Fail. 2012. Vol. 18. P. 626–634.
31. HFSA 2010 Comprehensive Heart Failure Practice Guideline / J. Lindenfeld// J. Card. Fail. 2010. Vol. 16. e1–e194.
32. Doust J. A. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review // BMJ (Clinical Research ed.). 2005. Vol. 330. P. 625.
33. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure–SIGNAL-HF (Swedish Intervention study – Guidelines and NT-proBNP AnaLysis in Heart Failure). / H. Persson// Eur. J. Heart Fail. 2010. Vol. 12. P. 1300–1308.
34. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study / A. A. Mohammed// Jr. Eur. J. Heart Fail. 2013. Vol. 15. P. 342–351.
35. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy / M. T. Maeder// Am. Heart J. 2012. Vol. 163. P. 407–414.
36. Latini R. Incremental prognostic value of changes in Btype natriuretic peptide in heart failure // Am. J. Med. 2006. Vol. 119. P. 70.
37. Araujo J. P. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure // Am. J. Cardiol. 2006. Vol. 98. P. 1248–1250.
38. Davis M. E. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure // Circulation. 2006. Vol. 113. P. 977–985.
39. Januzzi J. L. Jr. Use of biomarkers to ‘guide’ care in chronic heart failure: what have we learned (so far)? // J. Card. Fail. 2011. Vol. P. 622–625.
40. Kirsch В. Electron microscopy of the atrium of the heart // ExP. Med. Surg. 1956. Vol. 14. P. 99–111.
41. Schou М. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients // Eur. Heart J. 2007. Vol. 28. P. 177–182.
42. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study / L. W. Eurlings// J. Am. Coll. Cardiol. 2010. Vol. 56. P. 2090–2100.
43. Motiwala S. R., Januzzi J. L. Jr. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure // Clin. Pharmacol. Ther. 2012. Vol. 93. P. 57–67.
44. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials / G. Savarese// PLoS ONE. 2013. Vol. 8. P. 582–587.
45. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) / M. T. Maeder// Eur. J. Heart Fail. 2013. Vol. 15. P. 1148–1156.
46. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnea and ventricular dysfunction / A. Bayes-Genls// Eur. J. Heart Fail. 2004. Vol. 6. P. 301–308.
47. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial / J. G. Lainchbury// J. Am. Coll. Cardiol. 2009. Vol. 55. P. 53–60.
48. Berger R. N-terminal pro-B-type natriuretic peptideguided, inteintensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study // J. Am. Coll. Cardiol. 2010. Vol. 55. P. 645–653.
49. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients / P. Bettencourt// Circulation. 2004. Vol. 110. P. 2168–2174.
50. NT-ProBNP in acute heart failure: Correlation with invasiveh measured hemodynamic parameters during recompensation / F. Knebel// J Card Fail. 2005. Vol. 11 (5 Suppl.r S38-41).
51. Chen А. А. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy // Eur. Heart J. 2006. Vol. 27. P. 839–845.
52. Jourdain Р. Plasma brainnatriuretic peptide-guided therapy to improve outcome in heart failure: the STARSBNP Multicenter Study // J. Am. Coll. Cardiol. 2007. Vol. 49. P. 1733–1739.
53. Plasma natriuretic peptide levels and the risk of cardiovascular events and death / T. J. Wang// N. Engl. J. Med. 2004. Vol. 350. P. 655–663.
54. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model / D. S. Lee// JAMA. 2003. Vol. 290. P. 2581–2587.
55. Predischarge В-type natriuretic peptide assay for identifying patients at high risk of re-admissior after decompensated heart failure / D. Logeart// J. Am. Col. Cardiol. 2004. Vol. 43. P. 635–641.
56. Cleland J. Predicting the long-termeffects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial // J. Am. Coll. Cardiol. 2008. Vol. 52. P. 438–445.
57. Presence of dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure / J. A. Schirger// Mayo Clin. Proc. 1999. Vol. 74. P. 126–130.
58. Maisel А. Primary results of the HABIT Trial (heart failure assessment with BNP in the home) // J. Am. Coll. Cardiol. 2013. Vol. 61. P. 1726–1735.
59. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter Study of В-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath / A. Maisel// J. Am. Coll. Cardiol. 2004. Vol. 44. P. 1328–1333.
60. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial / I. S. Anand// Circ. Heart Fail. 2011. Vol. 4. P. 569–577.
61. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study / A. Bhardwaj// Am. Heart J. 2012. Vol. 164. P. 793–799.
62. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis / G. C. Fonarow// JAMA. 2005. Vol. 293. P. 572–580.
63. Roller K. J., Goeddel D. V. Molecular biology of the natriuretic peptides and their receptors // Circulation. 1992. Vol. 86. P. 1081–1088.
64. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF / Wijk S. Sanders-van// Eur. J. Heart Fail. 2013 Vol. 15. P. 910–918.
65. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure / A. Bayes-Genfs// Int. J. Cardiol. 2007. Vol. 120. P. 338–343.
66. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction / R. A. Weir// J. Am. Coll. Cardiol. 2010. Vol. 55. P. 243–250.
67. Kubanek М. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction // Eur. J. Heart Fail. 2009. Vol. 11. P. 367–377.
68. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure / M. R. Shah// J. Card. Fail. 2011. Vol. 17. P. 613–621.
69. Murdoch D. R. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy // Am. Heart J. 1999. Vol. 138 (6 Pt 1). P. 1126–1132.
70. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations / R. W. Troughton // Lancet. 2000. Vol. 355. P. 1126–1130.
71. Troughton R., Felker G. M., Januzzi J. L. Natriuretic peptide-guided heart failure Management // European Heart Journal. 2014 Vol. 35. P. 16–24.
72. Lenzen M. J. Under-utilization of evidence-baseddrug treatment in patients with heart failure is only partially explained by dissimilarityto patients enrolled in landmark trials: a report from the Euro Heart Survey on HeartFailure // Eur. Heart J. 2005. Vol. 26. P. 2706–2713.
73. Januzzi J. L. Use of amino-terminal Pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction // J. Am. Coll. Cardiol. 2011. Vol. 58. P. 1881–1889.